Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept

The founders of Lilly's radical Chorus experiment have left the mother ship to do the extraordinarily fast and inexpensive proof-of-concept development that have made Chorus one of the most interesting models in the industry. The two new entrepreneurs, backed by Versant, hope that their new company, Flexion, will be able to preferentially sign deals for the shelved molecules that a host of in-licensing start-ups have also been seeking.

In 2002, Eli Lilly & Co. began to experiment with a radically new process for clinical development: rapid proof-of-concept (POC). It was by no means the first such experiment in the industry, but Lilly has been the only company to stick with it, institutionalizing the ideas in its quasi-independent Chorus division (See "Lilly’s Chorus Experiment," IN VIVO, May 2007 Also see "Lilly's Chorus Experiment" - In Vivo, 1 May, 2007.).

Now Chorus’ two top executives are going out on their own, setting up a Chorus-style competitor called Flexion Therapeutics Inc.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D